HCPCS Level II code J1552 designates a 500 mg injection of immune globulin (alyglo), a biologic used for immunoglobulin replacement or immune modulation. Nationally, precise coding for immune globulin products drives accurate clinical documentation, claims processing, and cost tracking due to high unit costs and site-of-service variation. Clear identification of product-specific HCPCS codes is important for payers, providers, and patients managing therapy access and coverage.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1552 represents, how it is typically administered, and which sites of service are most common. The publication outlines expected benchmarks for code use, payer coverage considerations, and relevant policy or billing updates where applicable.

This summary equips clinicians, coders, and revenue-cycle managers with the clinical context and billing clarity needed for claims submission and benefit verification for immune globulin therapy. Data not available in the input is noted where applicable.